There is growing evidence for a graft-versus-myeloma effect following allogeneic stem cell transplantation. We add to this evidence by reporting complete remission achieved by withdrawal of immunosuppression in a patient with multiple myeloma progressing after HLAidentical sibling peripheral stem cell transplantation. De novo chronic graft-versus-host disease coincided with the anti-myeloma effect and responded to treatment. The patient remains in complete remission 3 years after transplant. Keywords: multiple myeloma; graft-versus-myeloma; graft-versus-leukemia; allogeneic stem cell transplantation
The graft-versus-leukemia effect (GVL) is important in eradicating residual leukemia after allogeneic stem cell transplantation (SCT). Clinical evidence for GVL is found in higher relapse rates after autologous or syngeneic transplants as compared to allogeneic transplants, and in higher relapse rates in patients without graft-versus-host disease (GVHD) or in recipients of T cell-depleted transplants. 1 Induction of GVL has become an important option for treatment of relapse after allogeneic SCT. [2] [3] [4] GVL can be induced by infusion of donor lymphocytes (DLI) and occasionally by rapid tapering of immunosuppression. These immunological interventions, supported occasionally by administration of cytokines (IFN-␣, IL-2) result in significant proportions of complete remissions.
2-5 GVL susceptibility differs among leukemias. Stronger GVL is observed in CML and weaker effects in patients with ALL. 3 High relapse rates of multiple myeloma (MM) after autologous SCT suggest that myeloablative conditioning regimens are incapable of eradicating the disease. Lower relapse rates after allogeneic SCT may be due to additional immunological reactivity of the allograft analogous to the well characterized GVL effect. 6 A graft-versus-myeloma (GVM) effect, is further demonstrated by response to DLI to treat relapsed myeloma after allogeneic SCT [7] [8] [9] [10] [11] [12] [13] has recently been reviewed. 8 However, data on GVM after withdrawal of immunosuppression are limited. We add to the ongoing discussion by documenting an impressive response to withdrawal of immunosuppression in a patient with multiple myeloma progressing after HLA-identical sibling transplantation.
Case report
A 37-year-old female was diagnosed with multiple myeloma IgG lambda, stage IIIA in January 1996. Diagnosis was based on presence of a major gammopathy of 45.7 g/l (normal values for ␥-globulins: 6.2-14.4 g/l), bone marrow infiltration with Ͼ30% atypical plasma cells, multiple osteolytic lesions (skull, humerus, pelvis, shoulder girdle), and trace positive Bence-Jones proteinuria. Hemoglobin was 12.5 g/dl, calcium, creatinine and ␤-2-microglobulin were within normal range. She was treated with three cycles of VAD (vincristine, adriamycin, dexamethasone) with minimal response: 14, 15 ␥-globulins decreased to 36.4 g/l, Bence-Jones proteinuria became negative, plasma cell infiltration of more than 30% persisted.
On 28 August 1996, she underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from her HLAidentical sister. The conditioning regimen consisted of VP-16 (30 mg/kg), cyclophosphamide (120 mg/kg), and total body irradiation (12 Gy in 6 fractions). 16 Peripheral stem cells were mobilized with 10 g/kg of G-CSF s.c. for 5 days with large volume apheresis on day 5. The transplant was not T cell depleted, CD34
+ cell content was 7.1 × 10 6 /kg, CFU-GM were 336 × 10 4 /kg. Cyclosporine (3 mg/kg) and short course methotrexate were given for GVHD prophylaxis. Details of the post-transplant course are shown in Table 1 . Engraftment was rapid with Ͼ500 neutrophils/l on day +16 and platelet transfusion independence on day +12. There was no acute GVHD or serious infections and the patient was discharged on day +24. Evaluation 1 month after PBSCT showed persistent myeloma with ␥-globulins of 20.5 g/l, persistent monoclonal IgG lambda on immunofixation and marrow plasmacytosis of 20%. Cyclosporine was withdrawn on day 35 with the intention of inducing a graft-versus-myeloma effect. By 2 months post transplant an increasing tumor load was evident with ␥-globulins at 30.9 g/l, plasma cell infiltration of the bone marrow at 50%, and trace positive Bence-Jones proteinuria. On day +70, the patient developed extensive de novo chronic GVHD involving the skin and mucous membranes (keratoconjunctivitis sicca), liver with a moderate increase in transaminases, general symptoms of weight loss of 4 kg and blood eosinophilia. GVHD improved upon institution of prednisone (30 mg/day) on day +80 and cyclosporine on day +90. Evaluation 3 months after PBSCT showed clear regression of tumor load. Bone marrow plasma cell content was normal, Bence-Jones proteinuria was negative, and paraproteinemia had decreased markedly (␥-globulins at 18.7 g/l). Complete remission with absence of any paraprotein on immunofixation was attained 1 year after PBSCT. Chimerism analysis by short tandem repeats of the peripheral blood showed only donor type DNA. Steroids were successfully withdrawn 16 months after PBSCT. Now, 3 years after allogeneic PBSCT the patient is well and in complete remission with limited chronic GVHD of skin and mucous membranes controlled by 200 mg/day of cyclosporine.
Discussion
This case demonstrates a GVM effect induced by abrupt discontinuation of immunosuppression in a patient with progressive myeloma despite allogeneic PBSCT. Evidence of GVM induction is based on the temporal relationship between withdrawal of immunosuppression, appearance of de novo GVHD, and tumor regression. Immunosuppression was withdrawn on day 35, GVHD appeared on day 70, and GVM became evident on day 90 after PBSCT. Immunosuppression was reinstituted to treat GVHD on day 80. Forty-five days without immunosuppression were apparently sufficient to allow GVM reactivity. It may be speculated that the expansion of pre-existing T cell clones after withdrawal of cyclosporine was necessary to mediate GvM. We cannot exclude, however, that de novo GVHD and GVM could have occurred without withdrawal of immunosuppression. Simultaneous appearance of GVHD does not allow differentiation between a tumor-specific response and the beneficial effect of GVHD alloreactivity. Currently, 3
years after PBSCT, the patient is in complete remission with limited chronic GVHD controlled by cyclosporine. This observation indicates that, effector clones mediating GVM, once expanded, continue to have a clinical impact despite reinstitution of immunosuppressive drugs. Impressive evidence of beneficial GVM effects comes from response to infusion of donor lymphocytes in patients relapsing after allogeneic transplantation. A review 8 of published case reports, 7,9-13 described responses to DLI in 21 of 32 relapsed MM patients. This response rate appears to be comparable to response rates in CML. Slowly proliferating diseases like CML and MM appear to be ideal targets for post-transplant immune interventions, as time is required to induce GVL/GVM responses. 17 Reports on the efficacy of rapid tapering of immunosuppressive drugs are rare. Two case reports describe GVHD and remission after withdrawal of immunosuppression in two CML and one Burkitt's lymphoma patient. 4, 18 An uncontrolled study of 26 patients with different diseases at high risk of relapse concluded that rapid tapering of immunosuppression was beneficial by tipping the balance towards more GVL. 19 One of these patients had persistent myeloma but no details are given.
Exploitation of GVM remains difficult and many patients develop GVHD, thus increasing transplant-related mortality. 6 Multiple myeloma patients are often elderly and age remains a major risk factor for transplant-related mortality. Future developments of immunosuppressive regimens may enable us to define strategies for using GVM without losing patients to complications of GVHD.
In summary, this case report strengthens the evidence for a GVM effect, demonstrating tumor response coinciding with GVHD after withdrawal of immunosuppression.
